Research programme: neurological disorders therapeutic - Innovation Pharmaceuticals

Drug Profile

Research programme: neurological disorders therapeutic - Innovation Pharmaceuticals

Alternative Names: KM-362

Latest Information Update: 09 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cellceutix
  • Developer Innovation Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Neurological disorders

Most Recent Events

  • 07 Jun 2017 Cellceutix is now called Innovation Pharmaceuticals
  • 03 Jun 2008 Early research in Neurological disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top